Nahdi Medical Earns 622.7M SAR in Nine Months

Riyadh, Saudi Arabia — Nahdi Medical Co. posted a net profit of 622.7 million SAR for the nine months ending September 30, 2026, down 4.9% from 654.8 million SAR in the same period last year. Revenue, however, grew 7.0% to 8,160.7 million SAR, reflecting strong momentum across retail, healthcare, and regional expansion. The profit decline signals a margin squeeze as the company absorbs higher costs tied to growth investments.

Q3 2026 Snapshot

Nahdi’s third quarter showed improvement on a year-over-year basis. Revenue rose 9.4% to 2,692.0 million SAR, up from 2,461.5 million SAR in Q3 2025. Net profit climbed 6.6% to 171.8 million SAR, compared to 161.2 million SAR a year earlier. However, sequentially, the picture weakened. Net profit fell 20.2% from 215.2 million SAR in Q2 2026, as gross margins compressed further due to a shift in business mix toward lower-margin healthcare and online channels.

Key Drivers

• Retail revenue grew 5.7% over nine months, led by both pharma and front-shop segments.
• Healthcare revenue surged 32.1% over the nine-month period; regional expansion rose 29.1%.
• Gross profit for nine months reached 2,952.3 million SAR, up 3.6%, but gross margin fell to 36.2% from 37.4% a year ago.
• Operating profit declined 2.3% to 701.5 million SAR, weighed down by higher expenses for strategic initiatives and digital investment.
• Below-the-line costs increased 15.4 million SAR versus the prior period, driven by lower finance income and a higher Zakat provision.
• Total shareholders’ equity rose 7.1% year-over-year to 2,695.8 million SAR.
• Earnings per share came in at 4.79 SAR, down from 5.04 SAR in the same period last year.

What This Means for Investors

• Revenue growth is real, but margin erosion is accelerating. Gross margin fell 120 basis points over nine months — investors should watch whether healthcare scale eventually reverses this trend.
• The sequential profit drop of 20.2% in Q3 versus Q2 is not a one-off. It reflects structural mix changes that Nahdi is actively choosing, not external shocks.
• The Zakat provision increase and lower Islamic investment income added pressure below the operating line — factors that could persist if interest-equivalent yields stay compressed.
• Shareholders’ equity growth of 7.1% and an unmodified auditor’s conclusion provide a stable baseline, but the gap between revenue growth (7%) and profit growth (-4.9%) demands close monitoring in Q4.

Saudi Arabia stock market investor news and earnings updates

Saudi capital markets analysis and listed company coverage

THE SAUDI STANDARD’S VIEW: NAHDI’S GROWTH-MARGIN TRADE-OFF DEMANDS INVESTOR ATTENTION

Nahdi Medical’s nine-month results present a company in deliberate transition — one that is choosing market capture over near-term profitability. For Saudi investors, the critical question is not whether margins have compressed, but whether the strategic bets now being placed will generate sustainable earnings power in the years ahead.

• REVENUE STRENGTH MASKS A DEEPENING MARGIN CHALLENGE

Top-line growth of 7.0% over nine months is a genuine operational achievement for a company operating at Nahdi’s scale in the Kingdom’s competitive pharmacy and healthcare retail sector. However, a 120-basis-point contraction in gross margin signals that cost absorption is outpacing revenue conversion efficiency. Investors must distinguish between a company growing through discipline and one growing through dilution of its core economics.

• HEALTHCARE AND DIGITAL PIVOT CARRIES STRUCTURAL CONSEQUENCES

The 32.1% surge in healthcare revenue and accelerating online channel activity reflect a deliberate repositioning away from traditional high-margin retail pharmacy toward service-intensive, lower-margin verticals. This is a calculated trade-off that mirrors trends across global pharmacy chains, where diversification eventually builds pricing power and patient loyalty. Saudi investors should assess whether Nahdi’s balance sheet and operational infrastructure are sufficiently robust to sustain this transition period without prolonged earnings pressure.

• SEQUENTIAL WEAKNESS IN Q3 IS A SIGNAL, NOT NOISE

A 20.2% quarter-on-quarter profit decline is material and reflects a business mix shift that management is actively engineering rather than reacting to external disruption. While the year-over-year Q3 improvement of 6.6% in net profit provides some comfort, the sequential deterioration warrants vigilance as Q4 results will determine whether this trend stabilizes or extends. Investors pricing Nahdi on forward earnings multiples should build conservatism into their margin assumptions for the near term.

• BALANCE SHEET STABILITY PROVIDES A CREDIBLE FLOOR

Shareholders’ equity expanding 7.1% year-over-year to 2,695.8 million SAR demonstrates that Nahdi’s growth investments are not undermining its financial foundations. This equity base, combined with steady operational cash generation implied by its revenue trajectory, affords the company meaningful flexibility to continue its expansion program across retail, healthcare services, and regional markets. For long-term investors, this structural solidity is the key risk mitigant against the current earnings softness.

Nahdi Medical’s strategic evolution aligns closely with Vision 2030’s ambition to build a world-class domestic healthcare sector, reduce reliance on imported medical services, and expand private sector participation in primary care delivery. As Saudi Arabia deepens investment in preventive health, digital health infrastructure, and regional medical tourism, companies capable of scaling across the full healthcare continuum will command a central role in the Kingdom’s economic transformation. Nahdi’s current margin pressure may ultimately prove to be the cost of positioning for that larger opportunity.